AAAAAA

   
Results: 1-24 |
Results: 24
Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core
Authors: Fevig, JM Pinto, DJ Han, Q Quan, ML Pruitt, JR Jacobson, IC Galemmo, RA Wang, SA Orwat, MJ Bostrom, LL Knabb, RM Wong, PC Lam, PYS Wexler, RR
Citation: Jm. Fevig et al., Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core, BIOORG MED, 11(5), 2001, pp. 641-645
Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists
Authors: Sielecki, TM Liu, J Mousa, SA Racanelli, AL Hausner, EA Wexler, RR Olson, RE
Citation: Tm. Sielecki et al., Synthesis and pharmacology of modified amidine isoxazoline glycoprotein IIb/IIIa receptor antagonists, BIOORG MED, 11(16), 2001, pp. 2201-2204
Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2 '- (methylsulfonyl)-[1,1 '-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa
Authors: Pinto, DJP Orwat, MJ Wang, SG Fevig, JM Quan, ML Amparo, E Cacciola, J Rossi, KA Alexander, RS Smallwood, AM Luettgen, JM Liang, L Aungst, BJ Wright, MR Knabb, RM Wong, PC Wexler, RR Lam, PYS
Citation: Djp. Pinto et al., Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2 '- (methylsulfonyl)-[1,1 '-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa, J MED CHEM, 44(4), 2001, pp. 566-578
Design and synthesis of a series of (2R)-N-4-hydroxy-2-(3-hydroxybenzyl)-N-1-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors
Authors: Yao, WQ Wasserman, ZR Chao, M Reddy, G Shi, E Liu, RQ Covington, MB Arner, EC Pratta, MA Tortorella, M Magolda, RL Newton, R Qian, MX Ribadeneira, MD Christ, D Wexler, RR Decicco, CP
Citation: Wq. Yao et al., Design and synthesis of a series of (2R)-N-4-hydroxy-2-(3-hydroxybenzyl)-N-1-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors, J MED CHEM, 44(21), 2001, pp. 3347-3350
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1 ', a series of selective TNF-alpha converting enzyme inhibitorswith potent cellular activity in the inhibition of TNF-alpha release
Authors: Xue, CB He, XH Corbett, RL Roderick, J Wasserman, ZR Liu, RQ Jaffee, BD Covington, MB Qian, MX Trzaskos, JM Newton, RC Magolda, RL Wexler, RR Decicco, CP
Citation: Cb. Xue et al., Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1 ', a series of selective TNF-alpha converting enzyme inhibitorswith potent cellular activity in the inhibition of TNF-alpha release, J MED CHEM, 44(21), 2001, pp. 3351-3354
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro andin vivo
Authors: Xue, CB Voss, ME Nelson, DJ Duan, JJW Cherney, RJ Jacobson, IC He, XH Roderick, J Chen, LH Corbett, RL Wang, L Meyer, DT Kennedy, K DeGrado, WF Hardman, KD Teleha, CA Jaffee, BD Liu, RQ Copeland, RA Covington, MB Christ, DD Trzaskos, JM Newton, RC Magolda, RL Wexler, RR Decicco, CP
Citation: Cb. Xue et al., Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro andin vivo, J MED CHEM, 44(16), 2001, pp. 2636-2660
Isoxazolines and isoxazoles as Factor Xa inhibitors
Authors: Pruitt, JR Pinto, DJ Estrella, MJ Bostrom, LL Knabb, RM Wong, PC Wright, MR Wexler, RR
Citation: Jr. Pruitt et al., Isoxazolines and isoxazoles as Factor Xa inhibitors, BIOORG MED, 10(8), 2000, pp. 685-689
Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists
Authors: Sielecki, TM Wityak, J Liu, J Mousa, SA Thoolen, M Wexler, RR Olson, RE
Citation: Tm. Sielecki et al., Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists, BIOORG MED, 10(5), 2000, pp. 449-452
The de novo design and synthesis of cyclic urea inhibitors of factor Xa: Optimization of the S4 ligand
Authors: Galemmo, RA Wells, BL Rossi, KA Alexander, RS Dominguez, C Maduskuie, TP Stouten, PFW Wright, MR Aungst, BJ Wong, PC Knabb, RM Wexler, RR
Citation: Ra. Galemmo et al., The de novo design and synthesis of cyclic urea inhibitors of factor Xa: Optimization of the S4 ligand, BIOORG MED, 10(3), 2000, pp. 301-304
Synthesis and activity studies of conformationally restricted alpha-ketoamide factor Xa inhibitors
Authors: Cacciola, J Fevig, JM Stouten, PFW Alexander, RS Knabb, RM Wexler, RR
Citation: J. Cacciola et al., Synthesis and activity studies of conformationally restricted alpha-ketoamide factor Xa inhibitors, BIOORG MED, 10(11), 2000, pp. 1253-1256
Antiplatelet therapies
Authors: Smallheer, JM Olson, RE Wexler, RR
Citation: Jm. Smallheer et al., Antiplatelet therapies, ANNU REP M, 35, 2000, pp. 103-122
Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis
Authors: Wong, PC Crain, EJ Knabb, RM Meade, RP Quan, ML Watson, CA Wexler, RR Wright, MR Slee, AM
Citation: Pc. Wong et al., Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis, J PHARM EXP, 295(1), 2000, pp. 212-218
Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics
Authors: Wong, PC Quan, ML Crain, EJ Watson, CA Wexler, RR Knabb, RM
Citation: Pc. Wong et al., Nonpeptide factor Xa inhibitors: I. Studies with SF303 and SK549, a new class of potent antithrombotics, J PHARM EXP, 292(1), 2000, pp. 351-357
Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors
Authors: Han, Q Dominguez, C Stouten, PFW Park, JM Duffy, DE Galemmo, RA Rossi, KA Alexander, RS Smallwood, AM Wong, PC Wright, MM Luettgen, JM Knabb, RM Wexler, RR
Citation: Q. Han et al., Design, synthesis, and biological evaluation of potent and selective amidino bicyclic factor Xa inhibitors, J MED CHEM, 43(23), 2000, pp. 4398-4415
Isoxazolines as potent antagonists of the integrin alpha(v)beta(3)
Authors: Pitts, WJ Wityak, J Smallheer, JM Tobin, AE Jetter, JW Buynitsky, JS Harlow, PP Solomon, KA Corjay, MH Mousa, SA Wexler, RR Jadhav, PK
Citation: Wj. Pitts et al., Isoxazolines as potent antagonists of the integrin alpha(v)beta(3), J MED CHEM, 43(1), 2000, pp. 27-40
Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3)
Authors: Batt, DG Petraitis, JJ Houghton, GC Modi, DP Cain, GA Corjay, MH Mousa, SA Bouchard, PJ Forsythe, MS Harlow, PP Barbera, FA Spitz, SM Wexler, RR Jadhav, PK
Citation: Dg. Batt et al., Disubstituted indazoles as potent antagonists of the integrin alpha(v)beta(3), J MED CHEM, 43(1), 2000, pp. 41-58
Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa
Authors: Fevig, JM Buriak, J Stouten, PFW Knabb, RM Lam, GN Wong, PC Wexler, RR
Citation: Jm. Fevig et al., Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor Xa, BIOORG MED, 9(8), 1999, pp. 1195-1200
Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors
Authors: Dominguez, C Duffy, DE Han, Q Alexander, RS Galemmo, RA Park, JM Wong, PC Amparo, EC Knabb, RM Luettgen, J Wexler, RR
Citation: C. Dominguez et al., Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors, BIOORG MED, 9(7), 1999, pp. 925-930
Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate
Authors: Wityak, J Tobin, AE Mousa, SA Wexler, RR Olson, RE
Citation: J. Wityak et al., Isoxazoline GPIIb/IIIa antagonists bearing a phosphoramidate, BIOORG MED, 9(2), 1999, pp. 123-126
Anticoagulants: Thrombin and factor Xa inhibitors
Authors: Fevig, JM Wexler, RR
Citation: Jm. Fevig et Rr. Wexler, Anticoagulants: Thrombin and factor Xa inhibitors, ANNU REP M, 34, 1999, pp. 81-100
Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action
Authors: Olson, RE Sielecki, TM Wityak, J Pinto, DJ Batt, DG Frietze, WE Liu, J Tobin, AE Orwat, MJ Di Meo, SV Houghton, GC Lalka, GK Mousa, SA Racanelli, AL Hausner, EA Kapil, RP Rabel, HR Thoolen, MJ Reilly, TM Anderson, PS Wexler, RR
Citation: Re. Olson et al., Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action, J MED CHEM, 42(7), 1999, pp. 1178-1192
Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1
Authors: Quan, ML Liauw, AY Ellis, CD Pruitt, JR Carini, DJ Bostrom, LL Huang, PP Harrison, K Knabb, RM Thoolen, MJ Wong, PC Wexler, RR
Citation: Ml. Quan et al., Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 1, J MED CHEM, 42(15), 1999, pp. 2752-2759
Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2
Authors: Quan, ML Ellis, CD Liauw, AY Alexander, RS Knabb, RM Lam, G Wright, MR Wong, PC Wexler, RR
Citation: Ml. Quan et al., Design and synthesis of isoxazoline derivatives as factor Xa inhibitors. 2, J MED CHEM, 42(15), 1999, pp. 2760-2773
Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa
Authors: Fevig, JM Cacciola, J Alexander, RS Knabb, RM Lam, GN Wong, PC Wexler, RR
Citation: Jm. Fevig et al., Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa, BIOORG MED, 8(22), 1998, pp. 3143-3148
Risultati: 1-24 |